<div>
  <ul>
    <li>
      <p>
        General telemedicine provider Dialogue Health Technologies' Q2 2023 results reported net loss per share of CAD 0.09 for the period, missing analyst expectations of a loss of CAD 0.05. Net losses reduced 31.4% YoY to CAD 5.8 million (USD 4.3 million) from CAD 8.4 million (USD 6.3 million) in Q2 2022.
      </p>
    </li>
    <li>
      <p>
        Revenue met expectations, growing 17.2% YoY to CAD 25.5 million (USD 19.0 million). Growth was primarily driven by a 18.6% increase in members, an expansion of the attach rate as existing customers added more services, and full-quarter contributions from Tictrac. The company also saw an average monthly net retention rate of 120% while experiencing no customer churn in the direct mid-market and enterprise customer segments. New members that onboarded the platform during the period nearly totaled 447,000, driven by Dialogue securing new customers through expansions and new partnerships, price increases, and the addition of Tictrac.
      </p>
    </li>
    <li>
      <p>
        Adjusted EBITDA losses for the period beat internal expectations, decreasing to CAD 0.9 million (USD 0.7 million) from CAD 4.5 million (USD 3.4 million) in Q2 2022. The company attributes the reduction in the loss to higher gross profits and strong cost control measures, partially offset by inflation-related cost increases across the business.
      </p>
    </li>
    <li>
      <p>
        Dialogue Health has not provided any forward-looking guidance as the company has entered into an agreement to be 
        <a href="https://investors.dialogue.co/English/news/news-details/2023/Dialogue-to-be-Acquired-by-Sun-Life/default.aspx">
          acquired by financial services company Sun Life Financial
        </a>
         for a consideration of CAD 365 million (USD 270 million) or CAD 5.15 (USD 3.82) per share. The transaction is expected to close in Q4 2023. Post acquisition, Dialogue will delist from the Toronto Stock Exchange but will continue to operate as a standalone entity under the &ldquo;Sun Life Canada&rdquo; brand from its head office in Qu&eacute;bec.&nbsp;
      </p>
    </li>
  </ul>
  <p>
  </p>
</div>


<div>
  <p>
    <a href="https://investors.dialogue.co/English/news/news-details/2023/Dialogue-Health-Technologies-Reports-Second-Quarter-2023-Results/default.aspx">
      Press release
    </a>
  </p>
  <p>
  </p>
</div>


Remote Work Tools

Telemedicine provider Dialogue Health Technologies reported a net loss per share of CAD 0.09 in Q2 2023, missing analyst expectations. However, net losses decreased by 31.4% compared to the same period last year. Revenue met expectations, growing by 17.2% YoY. The growth was driven by an increase in members, an expansion of services, and contributions from Tictrac. The company had a high average monthly net retention rate and no customer churn. Adjusted EBITDA losses decreased due to higher gross profits and cost control measures. Dialogue Health is set to be acquired by Sun Life Financial for CAD 365 million, with the transaction expected to close in Q4 2023.

Dialogue Health Technologies releases Q2 2023 results; plans to delist post-acquisition by Sun Life Financial

More important now than ever, telehealth will long outlast the pandemic that drove its growth.

All Updates

Dialogue Health Technologies releases Q2 2023 results; plans to delist post-acquisition by Sun Life Financial

Dialogue Health Technologies releases Q1 2023 results; meets internal expectations

Dialogue Health Technologies releases Q1 2023 results; meets internal expectations

Dialogue Health Technologies releases FY2022 results; posts recovering results

Dialogue Health reports 3Q 2022 results, misses analyst expectations but projects strong growth to close out the year

Dialogue narrowly misses analyst expectation for Q2 earnings

Dialogue narrowly misses analyst consensus